4D Molecular Therapeutics Inc (FDMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -140,109 | -159,506 | -102,630 | -47,972 | -160,868 |
| Depreciation Amortization | -40 | -109 | -216 | -216 | -2,529 |
| Accounts payable and accrued liabilities | 6,773 | 2,477 | 4,314 | -235 | 871 |
| Other Working Capital | 6,172 | 3,417 | -1,582 | -7,171 | 537 |
| Other Operating Activity | 18,122 | 16,088 | 8,979 | 7,836 | 27,404 |
| Operating Cash Flow | $-109,082 | $-137,633 | $-91,135 | $-47,758 | $-134,585 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -536 | -606 | -697 | -631 | -3,786 |
| Purchase Of Investment | -442,821 | -264,721 | -249,480 | -134,077 | -467,652 |
| Sale Of Investment | 350,384 | 301,201 | 268,273 | 166,656 | 169,001 |
| Investing Cash Flow | $-92,973 | $35,874 | $18,096 | $31,948 | $-302,437 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 19,420 | 978 | 862 | N/A | 337,250 |
| Other Financing Activity | 93,540 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | $112,960 | $978 | $862 | $N/A | $337,250 |
| Beginning Cash Position | 149,336 | 149,336 | 149,336 | 149,336 | 249,108 |
| End Cash Position | 60,241 | 48,555 | 77,159 | 133,526 | 149,336 |
| Net Cash Flow | $-89,095 | $-100,781 | $-72,177 | $-15,810 | $-99,772 |
| Free Cash Flow | |||||
| Operating Cash Flow | -109,082 | -137,633 | -91,135 | -47,758 | -134,585 |
| Capital Expenditure | -536 | -606 | -697 | -631 | -3,786 |
| Free Cash Flow | -109,618 | -138,239 | -91,832 | -48,389 | -138,371 |